E-ISSN: 2147-1959
Comparison of <sup>68</sup>Ga-PSMA PET/CT and <sup>18</sup>F-PSMA PET/CT of a Patient with Prostate Cancer Recurrence on Urinary Bladder Wall
PDF
Cite
Share
Request
Interesting Image
VOLUME: 32 ISSUE: 2
P: 150-152
June 2023

Comparison of 68Ga-PSMA PET/CT and 18F-PSMA PET/CT of a Patient with Prostate Cancer Recurrence on Urinary Bladder Wall

Mol Imaging Radionucl Ther 2023;32(2):150-152
DOI: 10.4274/mirt.galenos.2023.47550
Çiğdem Soydal
Burak Demir
Gizem Sütçü
Mine Araz
Nuriye Özlem Küçük
1. Ankara University Faculty of Medicine, Department of Nuclear Medicine, Ankara, Turkey
No information available.
No information available
Received Date: 05.10.2022
Accepted Date: 15.01.2023
Publish Date: 20.06.2023
PDF
Cite
Share
Request

ABSTRACT

Prostate cancer is one of the most prevalent cancers in the world. After radical prostatectomy, prostate-specific antigen (PSA) levels are usually used as a marker of recurrence for prostate cancer. In the case of increased PSA levels, 68Ga-prostate-specific membrane antigen (PSMA) or 18F-PSMA, a new alternative, can be performed for the detection of recurrent disease. We report a case of a 49-year-old male patient with increasing PSA levels who was previously operated 8 years ago. Although no obvious pathological uptake was detected in 68Ga-PSMA positron emission tomography/computed tomography (PET/CT), 18F-PSMA PET/CT revealed a lesion with pathological uptake on the urinary bladder wall.

References

1
Rebbeck TR. Prostate cancer genetics: variation by race, ethnicity, and geography. Semin Radiat Oncol 2017;27:3-10.
2
Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998;52:637-640.
3
Ghosh A, Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004;91:528-539.
4
Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, Giesel F, Haberkorn U, Hope TA, Kopka K, Krause BJ, Mottaghy FM, Schöder H, Sunderland J, Wan S, Wester HJ, Fanti S, Herrmann K. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging 2017;44:1014-1024.
5
Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, Kesch C, Tolstov Y, Singer S, Grabe N, Duensing S, Schäfer M, Neels OC, Mier W, Haberkorn U, Kopka K, Kratochwil C. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med 2017;44:678-688.